Hippocratic Growth Maryland Processing, LLC v. Pesce

CourtDistrict Court, D. Maryland
DecidedDecember 19, 2023
Docket1:22-cv-00090
StatusUnknown

This text of Hippocratic Growth Maryland Processing, LLC v. Pesce (Hippocratic Growth Maryland Processing, LLC v. Pesce) is published on Counsel Stack Legal Research, covering District Court, D. Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Hippocratic Growth Maryland Processing, LLC v. Pesce, (D. Md. 2023).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND

) HIPPOCRATIC GROWTH ) MARYLAND PROCESSING, LLC et al., ) ) Civil Action No. 22-cv-00090-LKG Plaintiffs/Counter-Defendants, ) ) Dated: December 19, 2023 v. ) ) MICHAEL PESCE, ) ) Defendant/Counter-Plaintiff. ) )

MEMORANDUM OPINION I. INTRODUCTION In this breach of contract action, Plaintiffs, Hippocratic Growth Maryland Processing, LLC (“Hippocratic”) and TC Maryland, Inc. (“TC Maryland”), allege that Defendant, Michael Pesce, breached a Stock Purchase Agreement that would have allowed Hippocratic to manage a Maryland medical cannabis processor. See generally, ECF No. 47. Hippocratic has moved to dismiss Mr. Pesce’s counterclaims for breach of contract (recission) and declaratory judgment, pursuant to Fed. R. Civ. P. 12(b)(6). ECF Nos. 41, 41-1, 54 and 54-1. This motion is fully briefed. ECF Nos. 42, 43, 55 and 57. No hearing is necessary to resolve the motion. See L.R. 105.6 (D. Md. 2021). For the reasons that follow, the Court: (1) GRANTS Hippocratic’s motion to dismiss Mr. Pesce’s counterclaims and (2) DISMISSES Mr. Pesce’s counterclaims in this matter. II. FACTUAL AND PROCEDURAL BACKGROUND1 A. Factual Background In this breach of contract action, Hippocratic alleges that Michael Pesce breached a Stock

1 The facts recited in this memorandum opinion are taken from the amended complaint (ECF No. 47); Mr. Pesce’s answer, affirmative defenses and counterclaims (ECF No. 48); Hippocratic’s motion to dismiss Purchase Agreement (the “SPA”) pursuant to which Hippocratic acquired 90 percent of the shares of TC Maryland and the ability to manage Pro Green Medical, LLC (“Pro Green”), a pre- approved Maryland medical cannabis processor. ECF No. 47 at ¶¶ 1-2; see ECF No. 11-2, Stock Purchase Agreement. Specifically, Hippocratic alleges that Mr. Pesce breached the SPA by refusing to communicate with the Maryland Medical Cannabis Commission (the “MMCC”) about an application to transfer the management of Pro Green to Hippocratic. ECF No. 47 at ¶¶ 25-26, 31. As relief, Hippocratic seeks to recover monetary damages from Mr. Pesce. Id. at ¶¶ 60, 66. The SPA As background, Hippocratic is a Maryland limited liability company that currently has a controlling interest in TC Maryland. Id. at ¶¶ 10, 18, 42. Michael Pesce was, from its formation until January 17, 2023, an officer and director of TC Maryland and he also serves as the LLC Manager of Pro Green. Id. at ¶¶ 1, 16. On February 18, 2021, Hippocratic and Mr. Pesce executed the SPA, pursuant to which Hippocratic acquired 90 percent of the shares of TC Maryland. Id. at ¶¶ 1, 15. At the time of this transaction, TC Maryland held an option to purchase 100 percent of the membership interests in Pro Green, an entity that is a licensed medical cannabis processor in the State of Maryland.2 Id. at ¶¶ 1-2. Central to the parties’ agreement was their plan to transfer the management of Pro Green to Hippocratic. See ECF No. 11-2, Stock Purchase Agreement at 7. To that end, Hippocratic agreed to pay Mr. Pesce $5,400,000.00, to provide additional funding to make Pro Green

Pesce’s counterclaims (ECF No. 41); the memorandum in support thereof (ECF No. 41-1); Mr. Pesce’s response in opposition thereto (ECF No. 42); Pesce’s memorandum in support thereof (ECF No. 42-1); Hippocratic’s reply in support of its motion to dismiss (ECF No. 43); Hippocratic’s memorandum in support thereof (ECF No. 43-1); Hippocratic’s renewed motion to dismiss (ECF No. 54); Hippocratic’s memorandum in support thereof (ECF No. 54); Mr. Pesce’s response in opposition thereto (ECF No. 55); Pesce’s memorandum in support thereof (ECF No. 55-1); Hippocratic’s reply in support of its renewed motion to dismiss (ECF No. 57); and Hippocratic’s memorandum in support thereof (ECF No. 57-1). Unless stated otherwise, the facts contained herein are undisputed.

2 A medical cannabis processing license entitles the processor to manufacture usable medical cannabis into medical cannabis concentrates or to manufacture medical cannabis-infused products (including edible cannabis products). ECF No. 47 at ¶ 2. operational and to provide a revolving line of credit for Pro Green’s operating expenses. Id. at 3, 13; see also ECF No. 47 at ¶ 18. Article VII of the SPA addresses termination of this agreement and Section 7.01 of the SPA provides that: ARTICLE VII TERMINATION Section 7.01 Notice of Default and Period to Cure. The Parties shall each devote all necessary time, attention and resources (financial or otherwise) to ensure that the Company obtains the MMCC Final Approval and Dispensary License by fulfilling their post-closing covenants and obligations. (a) If the Owner fails to satisfy (i) all post-closing covenants in Section 5.06 of this Agreement, or (ii) any other obligations under this Agreement and the Transaction Documents, Purchaser shall provide a written notice detailing the breach and requesting a meeting or conference call with the Owner for an explanation as to why the covenants and obligations have not been timely satisfied and how the Owner plans to fulfill his covenants and obligations within seven (7) Business Days after the meeting (“Owner Cure Period”). The meeting or conference call shall be scheduled within no more than two (2) business days after the notice. (b) If the Purchaser fails to satisfy all post-closing covenants in Sections 5.01, 5.02, 5.03, 5.04 and 5.05 and all other obligations under this Agreement and the Transaction Documents, the Owner shall provide written notice detailing the breach and requesting a meeting or conference call with the Purchaser for an explanation as to why the covenants and obligations have not been timely satisfied and how the Purchaser plans to fulfill all of its covenants and obligations within seven (7) Business Days after the meeting (“Purchaser Cure Period”). The meeting or conference call shall be scheduled within no more than two (2) Business Days after the notice. ECF No. 11-2, Stock Purchase Agreement at 19-20 (emphasis in original). It is undisputed that Hippocratic did not provide the notice described in Section 7.01(a) before it commenced this litigation. See ECF No. 28-1 at 8; ECF No. 31-1 at 5-7. Sections 7.02 and 7.03 of the SPA further provide that: Section 7.02 Termination of Agreement. At any time prior to the MMCC Final Approval and upon written notice to the other Party, this Agreement may be terminated as follows: 1. if, seven (7) Business Days after the expiration of the Owner Cure Period under 7.01(a), the Owner has not cured his breach of the post- closing covenants in this Agreement, the Purchaser may terminate this Agreement; 2. if, seven (7) Business Days after the expiration of the Purchaser Cure Period under 7.01(b), Purchaser has not cured its breach of the post- closing covenants in this Agreement, Seller Representative may terminate this Agreement; 3. by the mutual written consent of the Owner and Purchaser; 4. by Owner and Purchaser if there shall be any Law that makes consummation of the transactions contemplated by this Agreement illegal or otherwise prohibited; and 5. by Owner or Purchaser if any Governmental Body shall have issued a Governmental Order restraining or enjoining the transactions contemplated by this Agreement, and such Governmental Body shall have become final and non-appealable. Section 7.03 Effect of Termination. (a) The Parties’ termination rights under Section 7.02 are in addition to their rights under this Agreement or otherwise, and the exercise of any termination right will not be an election of remedies. (b) Nothing herein shall relieve any Party hereto from liability for any intentional breach of any provision hereof. ECF No. 11-2, Stock Purchase Agreement at 20.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

H. J. Inc. v. Northwestern Bell Telephone Co.
492 U.S. 229 (Supreme Court, 1989)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Nemet Chevrolet, Ltd. v. Consumeraffairs. Com, Inc.
591 F.3d 250 (Fourth Circuit, 2009)
Lazorcak v. Feuerstein
327 A.2d 477 (Court of Appeals of Maryland, 1974)
Finch v. Hughes Aircraft Co.
469 A.2d 867 (Court of Special Appeals of Maryland, 1984)
Kaser v. Financial Protection Marketing, Inc.
831 A.2d 49 (Court of Appeals of Maryland, 2003)
Blondell v. Littlepage
991 A.2d 80 (Court of Appeals of Maryland, 2010)
Funger v. Mayor of Somerset
223 A.2d 168 (Court of Appeals of Maryland, 1966)
Kemp v. Weber
24 A.2d 779 (Court of Appeals of Maryland, 1942)

Cite This Page — Counsel Stack

Bluebook (online)
Hippocratic Growth Maryland Processing, LLC v. Pesce, Counsel Stack Legal Research, https://law.counselstack.com/opinion/hippocratic-growth-maryland-processing-llc-v-pesce-mdd-2023.